View Cart  

Cispharma Gets Form 483 Over Testing, Drug Quality Concerns

A A
Cispharma has received a Form 483 with several manufacturing observations, including a lack of evidence that a distributed portion of a lot was acceptable.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $135.00